Bio-Techne Corp. stock falls 2.90% and underperforms competitors
Updated
Updated · MarketWatch · Apr 28
Bio-Techne Corp. stock falls 2.90% and underperforms competitors
7 articles · Updated · MarketWatch · Apr 28
Shares closed at $53.51 on Tuesday, ending a two-day winning streak and finishing 25.85% below the 52-week high of $72.16.
The decline occurred during a broadly negative market session, with the S&P 500 down 0.49% and the Dow Jones down 0.05%.
Bio-Techne's trading volume was 1.6 million, significantly below its 50-day average, while competitors like Amgen and BioMarin also saw smaller declines.
Is Bio-Techne's flat organic growth the real story behind its recent stock market plunge?
Beating earnings but its stock is falling, is Bio-Techne's high valuation a bubble about to burst?
Can Bio-Techne's tools help pharma giants survive the upcoming multi-billion dollar patent cliff?
As AI reshapes drug discovery, is Bio-Techne innovating fast enough to remain a key player?
How will Bio-Techne’s new synthetic product capitalize on the FDA's push away from animal testing?